EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load

Lassina Traore1,2, Ouéogo Nikiema1,2, Abdoul Karim Ouattara1,2, Tegwindé Rébéca Compaore1,2, Serge Théophile Soubeiga1,2, Birama Diarra1,2, Dorcas Obiri-Yeboah3, Pegdwendé Abel Sorgho1,2, Florencia Wendkuuni Djigma1,2, Cyrille Bisseye1,2, Albert Théophane Yonli1,2 and Jacques Simpore1,2

1 Biomolecular Research Center Pietro Annigoni (CERBA)
2 LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.
3 Deparment of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana

Corresponding author: Lassina Traore. Biomolecular Research Center Pietro Annigoni (CERBA)/LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph Ki-Zerbo, BP 364 Ouagadougou, Burkina Faso. Burkina Faso, West Africa. Tel: +226 76 50 37 05. E-mail:

Published: September 1, 2017
Received: June 13, 2017
Accepted: August 5, 2017
Mediterr J Hematol Infect Dis 2017, 9(1): e2017049 DOI 10.4084/MJHID.2017.049
This article is available on PDF format at: 

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso.
The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1.  The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping.
An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% [9/238] for EBV-1 vs 4.6% [11/238] for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients.
The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.


In the human species, there are eight (8) herpes viruses, including herpes simplex types 1 and 2 (HSV1 and HSV2), Varicella Zoster Virus (VZV), cytomegalovirus (CMV), Epstein-Barr Virus (EBV) and herpesviruses (HHV6, HHV7 and HHV8 associated with Kaposi's sarcoma).[1] They belong to the human herpesviridae family, and the high similarity between these viruses shows that they have a common origin.[1]
EBV is one of the most common human viruses, and it is found all over the world. Recent studies have shown that EBV seroprevalence is estimated to be present in more than 90% of adults older than 35 years of age worldwide.[2] Each year, new infections are estimated at 200,000.[3] The Epstein-Barr virus is commonly acquired during childhood in developing countries (more than 90% of pre-school children). In developed countries, many people are not infected in childhood but are rather infected in adolescence or during adulthood. Variations in the EBV genome made it possible to distinguish two (02) subtypes of the virus: EBV-1 and EBV-2 (or EBV-A and EBV-B types).[4] Seroprevalence studies have shown that EBV-1 strain predominates in western countries, whereas EBV-2 strain is only common in some areas of Equatorial Africa and New Guinea.[4] Primary infection with EBV is often asymptomatic or is responsible for infectious mononucleosis[5] and generally with no serious complications.[6] On the other hand, chronic infection is reported in many cases of cancers (gastric carcinoma, Burkitt's lymphoma [BL to nasopharyngeal carcinoma, Hodgkin's classic lymphoma (LH), gastric carcinoma][7-10] and oral hairy leukoplakia.[11] Furthermore, it is suggested that EBV is associated with brain cancer, salivary gland tumors, hepatocellular carcinoma[4] and also with certain autoimmune diseases such as multiple sclerosis,[12] especially in immunocompromised individuals.[13]
In most HIV-infected persons with progressive immunodeficiency, the number of EBV infected B cells increases in blood circulation[14] and can develop opportunistic lymphomas (Burkitt's lymphoma, lymphomas that diffuse to large cells and primitive cerebral lymphomas) all associated with EBV.
Human herpesvirus 6 (HHV-6) is a member of the beta-herpes virus family, genetically close to cytomegalovirus (CMV) and human herpesvirus 7 (HHV-7).[15] It is responsible for infection of the vast majority of children in the early years of life and persists like the majority of the others herpes viruses in the latent form after the primary infection. It is a ubiquitous virus that infects T lymphocytes, monocytes, macrophages, certain epithelial cells and central nervous system cells. It early appeared that there were two HHV-6 variants or subtypes, subtype A (HHV-6A) and subtype B (HHV-6B) defined according to antigenic, genetic and potential differences in their respective pathogenicity.[16] The seroprevalence of HHV-6 infection is estimated to be between 70 and 100% in the human population and varies according to geographic location.[17] In the United States and Japan, primary HHV-6 infection affects children between 6 and 12 months, and it is estimated to be between 97 and 100%. This primary infection is due to HHV-6B subtype,[18] and HHV-6B viral DNA is also frequently detected in children in parts of Sub-Saharan Africa where HIV-1 is endemic.[19] There are limited data available on HHV-6A prevalence in sub-Saharan Africa. Studies have shown that HHV-6A is acquired late in life with a primary infection, generally asymptomatic.[17] However, more recent studies have described symptomatic primary infection in American and African children including roseola and febrile diseases.[19] HHV-6B is the causative agent of a very young child benign disease, exanthema subitum, still called infantile roseola or sixth disease.
HHV-6A has mainly a neurological tropism. HHV-6A and HHV-6B also cause opportunistic infections in immunocompromised individuals, including systemic infections and organ disorders, particularly encephalitis, hepatitis, colitis, spinal cord insufficiency, pneumonia, interstitial pneumonitis.[20] It can also favor insurgency of acute lymphoblastic or non-lymphoblastic leukemias, cutaneous T-cell lymphoma, immunoblastic lymphoma, acute lymphoid leukemia[21] and Hodgkin's lymphoma.[19,22] Recently, HHV-6 has been described to be associated with Drug Rash with Eosinophilia and Systemic Symptoms.[23] The literature reported that HHV-6 and HIV-1 would act in concert by infecting and causing CD4+ T cell lysis, thereby accentuating immunosuppression and progression towards AIDS by accelerating the death of infected CD4+ T cells.[24-26] However, HHV-6 detection in the blood decreases with AIDS progression, since virus replication target cells, the CD4+ T cells, are reduced.[27] In HIV infected patients, HHV-6 reactivation are associated with encephalitis,[28] pneumonia[29] or retinitis.[30,31] It is currently unknown whether HHV-6 acts simply as an opportunistic pathogen or in synergy with HIV on the disease progression. Some of our previous studies have resulted in the detection of EBV, HHV-6, and CMV among blood donors[32,33] and HIV-positive mothers.[34] These studies also made possible to determine the molecular epidemiology of these herpes viruses in the subpopulations concerned by the latter studies. To date, there are no studies that revealed information on the subtypes of circulating EBV and HHV-6 in Burkina Faso. Thus, the present study not only targets the characterization of EBV and HHV-6 subtypes; but also the impact of infection of both viruses on CD4 T cell count, HIV-1 viral load, and treatment in people living with HIV-1.

Materials and Methods

Study setting. This prospective study was carried out in Ouagadougou, Burkina Faso from May 2016 to March 2017. The samples were collected at the Saint Camille Hospital of Ouagadougou (HOSCO), and the molecular analyses were carried out at the Molecular Biology and Genetics Laboratory (LABIOGENE) of the University Ouaga I Prof. Joseph KI-ZERBO and the Pietro Annigoni Biomolecular Research Center (CERBA).
Sampling. The study included 238 HIV-1 positive patients recruited during their routine visit at HOSCO. The samples consisted of 3 mL of venous blood collected in EDTA tubes. The whole blood was aliquoted and stored at -20°C until DNA extraction for molecular analysis. Sociodemographic characteristics, CD4 T cell count and HIV-1 viral load results were collected in patient follow-up registries with their free and informed consent.
DNA extraction and qualitative diagnosis of HHV-6 and EBV by real-time PCR. Genomic DNA was extracted from whole blood using the standard salting-out method as previously described by Miller et al.[35] EBV and HHV-6 subtypes identification was carried out by real-time PCR using specific primers and probes previously described by Kwok et al. for EBV and Yavarian et al. for HHV-6.[36,37]
The amplification for two viruses subtyping was carried out at 95°C for 5 minutes corresponding to initial denaturation, followed by 45 cycles of 95°C for 15 seconds and 55°C for 30 seconds.
Statistical analysis. A database was compiled on Microsoft Excel 2013 and then analyzed using the software Epi InfoTM 7 and Statistical Package for Social Sciences (SPSS) 21.0 (IBM, Armonk, NY, USA). The results were analyzed according to socio-demographic characteristics, clinical parameters, CD4 T cell count and HIV-1 plasmatic viral load. The chi-square test was used for the comparisons, and the difference was considered statistically significant for P value ≤ 0.05. 
Ethical considerations. Our study was approved by the Ethics Committee on Health Research (CERS) of Burkina Faso (Ref: DELIBERATION N° 2014-9-113). Written informed consent was obtained from all the participants, and the results confidentiality was respected. 


Socio-demographic characteristics. Our study involved 238 people living with HIV-1 (PLHIV-1). The study population consisted of 66.8% of women and 33.2% of men. Children under five years of age accounted for 9.7% of the study population while 90.3% of the individuals were over 15 years of age. The median age was 24.7 ± 18.9 years.
Prevalence of Herpes Virus Infections. Of the 238 patients tested in this study, 13.0% (31/238) were positive for at least one of the viruses (EBV or HHV-6). The prevalence of EBV, EBV-1 and EBV-2 was 6.7% (16/238); 3.9% (9/238) and 4.6% (11/238) respectively. EBV-1/EBV-2 co-infection was observed in 2.1% (5/238) patients of the study population. HHV-6 infections were detected in 7.1% (17/238) of the individuals with prevalence of 6.3% (15/238) and 5.0% (12/238) respectively for HHV- 6A and HHV-6B. HHV-6A/HHV-6B co-infection was observed in 10 patients or a prevalence of 4.2% (10/238). Two (2/238 or 0.8%) patients were co-infected with EBV/HHV-6. According to age, herpes infection was more observed in patients more than fifteen (15) years, except HHV-6B which was more observed in the group of more than 15 years old (Table 1 and Table 2). However, it should be noted that these results were not statistically significant.
Analysis of the results by sex showed that infections were more common in men than in women, except for the higher prevalence of HHV-6A in males compared to females (Table 1 and 2).
The difference between EBV prevalence in men and woman was slightly significant (P = 0.05).

Table 1 Table 1.  Prevalence of Herpes and EBV by sex, age, CD4 T cell count, viral load and treatment.

Table 2 Table 2. Prevalence and HHV-6 by sex, age, CD4 T cell count, viral load and treatment.

Herpes virus infections and CD4 cell count. Depending on the CD4 T cell count, our results show that patients with high CD4 T cell counts (CD4 T cell count ≥ 500/mL) are the most infected with herpes virus, EBV, EBV-1, and EBV-2. (Table 1). This difference was very significant for EBV-2 (P = 0.011) but was not significant for the others. HHV-6, HHV-6A and HHV-6B infections were more common in patients with low CD4 counts (CD4 T cell count < 500/mL) or those with high CD4 counts (CD4 T cell count ≥ 500 / mL) (Table 2). It should be noted that this difference was not statistically significant.
Herpes viral infections and HIV viral load. Our results were also analyzed according to the patients HIV-1 plasma viral loads. This analysis showed that patients with a low viral load (VL < 1000 copies/mL) were the most infected except for EBV-1 and HHV-6A which were more common in patients with high viral loads (VL > 1000 copies/mL) (Table 1 and 2). However, these differences were not statistically significant.
Herpes virus infections and ARV treatment. The analysis of the results according to ARV treatment (Table 1 and 2), showed that patients on ARV treatment were the most infected with herpes viruses, EBV, EBV-1, EBV-2, and HHV-6A. Meanwhile, the individuals, naïve to the treatment were more infected by HHV-6A and HHV-6B (Note that these patients were all co-infected with HHV-6A/HHV-6B). These results were not statistically significant.


The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their infections impact on CD4 T cell count, HIV-1 viral load and treatment in people living with HIV-1.
Our study focused on 238 PL-HIV and showed that the prevalence of EBV and HHV-6 was 6.7% and 7.1% respectively in our study population. These results are similar to those reported by Tao et al. with a prevalence of 5.4% for EBV among blood donors in Burkina Faso.[32] Our results are also consistent with those reported by Traoré et al. (5.1% and 6.0% respectively for EBV and HHV-6) in blood donors and Ouedraogo et al. (6.0% and 6.1% respectively for EBV and HHV-6) in pregnant women in Burkina Faso.[33,34] These findings suggest that the prevalence of herpes viruses determined by qualitative real-time PCR method are much lower compared to their seroprevalence. These results confirm that most people infected with herpes virus in the course of their lives are more likely to have a latent infection without viremia than a cleared infection.
This study has allowed us to characterize for the first time EBV and HHV-6 subtypes circulating in Burkina Faso. We found that EBV-1 (3.9%) and EBV-2 (4.6%) subtypes predominate with approximately the same proportions. Our results corroborate data from the literature showing that EBV-1 subtype is more prevalent in Europe, North America, and Asia; while a predominance of both subtypes is observed in Africa and New Guinea.[38-43] EBV-2 is also found in HIV-infected Europeans and Australians,[44-46] and approximately 20% of the healthy population in North America is co-infected with both subtypes.[47]
The subtyping of HHV-6 shows that HHV-6A and HHV-6B subtypes are both present in our study population with similar proportions of 6.3% and 5.0% respectively for HHV-6A and HHV-6B. The literature suggests that HHV-6B is found throughout the world while HHV-6A is less common in Asia, North America and Europe.[16] Primary HHV-6 infection is due to 86-100% of cases in subtype A (HHV-6A) in African children.[19] Our results are similar to those reported in the literature. Thus, in their study, Baillargeon et al. found a lower rates of HHV-6 shedding in the genital tract of pregnant, 7/297 [2.0%]; non-pregnant, 8/214 [3.7%] women; of 14 samples subtyped, four (29%) were subtype A.[48] whereas our study shows a slight prevalence of HHV-6A compared to HHV-6B even if these differences are not significant.
The analysis of our data according to the different age groups did not give any significant results for neither EBV, HHV-6 nor for the corresponding sub-types. However, the highest prevalence of overall infection with these two viruses was observed in the group of individuals who were less than five years old.
According to sex, men were more infected with both viruses as well as the corresponding subtypes. This result is especially significant for EBV infection.
Analysis of our data by CD4 T cell count and HIV-1 viral load shows that herpes infection is more common in patients with high CD4 T cell counts and those with a low viral load compared to patients with low CD4 T cell count and a high HIV viral load. This result is particularly significant for EBV. We also found that the prevalence of herpes viruses were high in HAART patients compared with those who were not under treatment. Our results corroborate those of Piriou et al. who have shown that although HAART treatment improves CD4 T cell restoration while contributing to lower HIV viral load, it did not affect EBV infection.[49] Thus, it is possible that herpes infection is more likely to be found in HAART patients with high CD4 T cell counts. This hypothesis is also supported by several studies which have shown that herpes/HIV co-infection further enhances CD4 T cell proliferation and thus broadens the types of target cells susceptible to HIV infection,[24,49-52] resulting in a high HIV viral load. Our results corroborate those of Erwan Piourou et al.,[49] Who also concluded that even in the long term HAART treatment does not reduce the herpes viral load, but above all, it makes it possible to fight against reactivation cases.


This study made it possible to characterize the subtypes of EBV and HHV-6. It showed the subtypes EBV-1, EBV-2, HHV-6A, and HHV-6B all circulating in Burkina Faso with almost identical proportions. We also support the hypothesis that HIV HAART treatment would not act on herpes virus infection but could prevent reactivation of these viruses.


The authors would like to thank Saint Camille Hospital of Ouagadougou (HOSCO) and Biomolecular Research Center Pietro Annigoni (CERBA). They express their gratitude to the Italian Episcopal Conference (CEI) and the West African Economic and Monetary Union (WAEMU) through the PACER2 program.


  1. Damania B. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol. 2004; 28:656-668. PMid:15263900        
  2. Balfour HH, Jr., Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013; 2071:80-88. PMid:23100562 PMCid:PMC3523797      
  3. Bagan L, Ocete-Monchon MD, Leopoldo-Rodado M, Murillo-Cortes J, Diaz-Fernandez JM, Medina-Gonzalez R, Gimeno-Cardona C, Bagan JV. Prevalence of salivary Epstein-Barr virus in potentially malignant oral disorders and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2016; 212:e157-160. PMCid:PMC4788793      
  4. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis. 2003; 33:131-140.       
  5. Godshall SE, Kirchner JT. Infectious mononucleosis. Complexities of a common syndrome. Postgrad Med. 2000; 1077:175-179, 183-174, 186.      
  6. Wang X, Yang K, Wei C, Huang Y, Zhao D. Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis. Virol J. 2010; 7:247. PMid:20858235 PMCid:PMC2949848      
  7. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958; 46197:218-223.       
  8. Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol Pathol. 2000; 535:262-269.       
  9. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis. 2008; 8:111. PMid:18706107 PMCid:PMC2528010      
  10. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses. 2012; 412:3420-3439. PMCid:PMC3528272      
  11. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol. 2000; 7416:7610-7618.       
  12. Munz C, Lunemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol. 2009; 94:246-258. PMid:19319143 PMCid:PMC2854652      
  13. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 496:1374-1403. PMid:23485231        
  14. van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, Niesters HG, Osterhaus AD, McMichael AJ, van Oers MH, Miedema F. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood. 2001; 981:146-155.      
  15. Mazeron M-C, Amiel C, Agut H. Mesure et interprétation des charges virales dans les infections à herpèsvirus humains (cytomégalovirus, virus Epstein-Barr, herpèsvirus humains 6 et 8). Revue Francophone des Laboratoires. 2016; 2016487:47-54.       
  16. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N, Gallo R, Gompels UA, Hollsberg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T. Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol. 2014; 1595:863-870. PMid:24193951 PMCid:PMC4750402      
  17. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005; 181:217-245. PMid:15653828 PMCid:PMC544175      
  18. Thader-Voigt A, Jacobs E, Lehmann W, Bandt D. Development of a microwell adapted immunoblot system with recombinant antigens for distinguishing human herpesvirus (HHV)6A and HHV6B and detection of human cytomegalovirus. Clin Chem Lab Med. 2011; 4911:1891-1898.       
  19. Bates M, Monze M, Bima H, Kapambwe M, Clark D, Kasolo FC, Gompels UA. Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa. J Med Virol. 2009; 815:779-789. PMid:19319952        
  20. Caserta MT, Mock DJ, Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001; 336:829-833. PMid:11512088        
  21. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, Halligan G, Biberfeld P, Wong-Staal F, Kramarsky B, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science. 1986; 2344776:596-601.      
  22. Torelli G, Marasca R, Luppi M, Selleri L, Ferrari S, Narni F, Mariano MT, Federico M, Ceccherini-Nelli L, Bendinelli M, et al. Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction. Blood. 1991; 7710:2251-2258      .
  23. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, Belaich S, Crickx B. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001; 1373:301-304.      
  24. Lusso P, Ensoli B, Markham PD, Ablashi DV, Salahuddin SZ, Tschachler E, Wong-Staal F, Gallo RC. Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature. 1989; 3376205:370-373. PMid:2463490        
  25. Kositanont U, Wasi C, Wanprapar N, Bowonkiratikachorn P, Chokephaibulkit K, Chearskul S, Chimabutra K, Sutthent R, Foongladda S, Inagi R, Kurata T, Yamanishi K. Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. J Infect Dis. 1999; 1801:50-55. PMid:10353860        
  26. Emery VC, Atkins MC, Bowen EF, Clark DA, Johnson MA, Kidd IM, McLaughlin JE, Phillips AN, Strappe PM, Griffiths PD. Interactions between beta-herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. J Med Virol. 1999; 573:278-282.<278::AID-JMV11>3.0.CO;2-3       
  27. Fairfax MR, Schacker T, Cone RW, Collier AC, Corey L. Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts. J Infect Dis. 1994; 1696:1342-1345.       
  28. Knox KK, Harrington DP, Carrigan DR. Fulminant human herpesvirus six encephalitis in a human immunodeficiency virus-infected infant. J Med Virol. 1995; 453:288-292.      
  29. Nigro G, Luzi G, Krzysztofiak A, D'Orio F, Aiuti F. Detection of IgM antibodies to human herpesvirus 6 in Romanian children with nonprogressive human immunodeficiency virus disease. Pediatr Infect Dis J. 1995; 1410:891-894.       
  30. Qavi HB, Green MT, Lewis DE, Hollinger FB, Pearson G, Ablashi DV. HIV-1 and HHV-6 antigens and transcripts in retinas of patients with AIDS in the absence of human cytomegalovirus. Invest Ophthalmol Vis Sci. 1995; 3610:2040-2047.      
  31. Reux I, Fillet AM, Agut H, Katlama C, Hauw JJ, LeHoang P. In situ detection of human herpesvirus 6 in retinitis associated with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992; 1143:375-377.       
  32. Tao I, Bisseye C, Nagalo BM, Sanou M, Kiba A, Surat G, Compaore TR, Traore L, Nikiema JB, Pietra V, Zongo JD, Simpore J. Screening of Hepatitis G and Epstein-Barr Viruses Among Voluntary non Remunerated Blood Donors (VNRBD) in Burkina Faso, West Africa. Mediterr J Hematol Infect Dis. 2013; 51:e2013053. PMid:24106603 PMCid:PMC3787664      
  33. Traore L, Tao I, Bisseye C, Diarra B, Compaore TR, Nebie Y, Assih M, Ouedraogo A, Zohoncon T, Djigma F, Ouermi D, Barro N, Sanou M, Ouedraogo RT, Simpore J. Molecular diagnostic of cytomegalovirus, Epstein Barr virus and Herpes virus 6 infections among blood donors by multiplex real-time PCR in Ouagadougou, Burkina Faso. Pan Afr Med J. 2016; 24:298. PMid:28154653 PMCid:PMC5267872      
  34. Ouedraogo AR, Kabre M, Bisseye C, Zohoncon TM, Asshi M, Soubeiga ST, Diarra B, Traore L, Djigma FW, Ouermi D, Pietra V, Barro N, Simpore J. [Molecular tests in diagnosis of Cytomegalovirus (CMV), human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) using real-time PCR in HIV positive and HIV-negative pregnant women in Ouagadougou, Burkina Faso]. Pan Afr Med J. 2016; 24:223. PMid:27800078 PMCid:PMC5075482      
  35. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 163:1215.      
  36. Kwok H, Chan KW, Chan KH, Chiang AK. Distribution, persistence and interchange of Epstein-Barr virus strains among PBMC, plasma and saliva of primary infection subjects. PLoS One. 2015; 103:e0120710. PMid:25807555 PMCid:PMC4373854      
  37. Yavarian J, Shatizadeh Malekshahi S, Yavarian R, Yazdani S, Janani L, Shafiei Jandaghi NZ, Kiani SJ, Ahamadkhaniha H. Type specific Real time PCR for detection of human herpes virus 6 in schizophrenia and bipolar patients: a case control study. BMC Psychiatry. 2015; 15:296. PMid:26584549 PMCid:PMC4653940      
  38. Abdel-Hamid M, Chen JJ, Constantine N, Massoud M, Raab-Traub N. EBV strain variation: geographical distribution and relation to disease state. Virology. 1992; 1901:168-175.      
  39. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009; 1432:209-221. PMid:19596032 PMCid:PMC2731007      
  40. Correa RM, Fellner MD, Alonio LV, Durand K, Teyssie AR, Picconi MA. Epstein-barr virus (EBV) in healthy carriers: Distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene. J Med Virol. 2004; 734:583-588. PMid:15221903      
  41. Falk KI, Zou JZ, Lucht E, Linde A, Ernberg I. Direct identification by PCR of EBV types and variants in clinical samples. J Med Virol. 1997; 514:355-363.<355::AID-JMV15>3.0.CO;2-H       
  42. Kunimoto M, Tamura S, Tabata T, Yoshie O. One-step typing of Epstein-Barr virus by polymerase chain reaction: predominance of type 1 virus in Japan. J Gen Virol. 1992; 73 (Pt 2):455-461. PMid:1311368        
  43. Sixbey JW, Shirley P, Chesney PJ, Buntin DM, Resnick L. Detection of a second widespread strain of Epstein-Barr virus. Lancet. 1989; 28666:761-765.       
  44. Sculley TB, Apolloni A, Hurren L, Moss DJ, Cooper DA. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis. 1990; 1623:643-648.      
  45. van Baarle D, Hovenkamp E, Kersten MJ, Klein MR, Miedema F, van Oers MH. Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood. 1999; 9311:3949-3955.      
  46. Yao QY, Tierney RJ, Croom-Carter D, Dukers D, Cooper GM, Ellis CJ, Rowe M, Rickinson AB. Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J Virol. 1996; 708:4884-4894.      
  47. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein-Barr virus infections in healthy individuals. J Virol. 2003; 7711:6546-6550. PMCid:PMC155020      
  48. Baillargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. J Clin Virol. 2000; 163:149-157.      
  49. Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol. 2005; 1753:2010-2017.       
  50. Ensoli B, Lusso P, Schachter F, Josephs SF, Rappaport J, Negro F, Gallo RC, Wong-Staal F. Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J. 1989; 810:3019-3027.      
  51. Lusso P, De Maria A, Malnati M, Lori F, DeRocco SE, Baseler M, Gallo RC. Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature. 1991; 3496309:533-535. PMid:1846951       
  52. Lusso P, Malnati MS, Garzino-Demo A, Crowley RW, Long EO, Gallo RC. Infection of natural killer cells by human herpesvirus 6. Nature. 1993; 3626419:458-462. PMid:7681936        


Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2017 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185